Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ: DMAC )

5.705 -0.095 (-1.64%)
Streaming Delayed Price Updated: 10:31 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,995
Open 5.700
Bid (Size) 5.630 (1)
Ask (Size) 5.780 (1)
Prev. Close 5.800
Today's Range 5.680 - 5.795
52wk Range 2.140 - 6.818
Shares Outstanding 37,953,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire

Performance

YTD
+3.54%
+3.54%
1 Month
-10.58%
-10.58%
3 Month
+5.06%
+5.06%
6 Month
+30.25%
+30.25%
1 Year
+97.40%
+97.40%

More News

Read More
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: DiaMedica Therapeutics's Earnings
Via Benzinga
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
DiaMedica Therapeutics Upcoming Conference Participation
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.